Breast cancer remains one of the most common cancers worldwide, but its progression is shaped not only by genetic mutations but also by the immune system’s interaction with developing tumors. Subtle molecular and immune changes often appear long before tumors become visible on imaging, providing an opportunity for earlier detection and intervention.

The Breast Immunocarcinogenic Assay analyzes biomarker patterns that reveal immune system activation, tumor-promoting inflammation, and prometastatic signaling. This assay provides clinicians with actionable molecular insights to guide risk assessment, early diagnosis, and personalized care strategies.

Why This Test Matters

Key Benefits

Standard scans can miss early immune and molecular changes. The Breast Immunocarcinogenic Assay detects these disruptions at the molecular level so patients and clinicians can act early.

Early Detection Potential

Identifies immune and molecular signals before traditional imaging or pathology.

Personalized Care

Supports precision medicine by highlighting immune pathways relevant to targeted therapies.

Treatment Monitoring

Tracks biomarker changes during therapy and in remission.

Complementary Diagnostic Value

Enhances mammography and biopsy findings with immune-molecular context.

Physician-Ready Report Included

Results in
10-14 days

Reliable Results You Can Trust

Biomarkers Assessed

The Breast Immunocarcinogenic Assay panel measures a targeted range of biomarkers to detect immune activity, tumor-promoting inflammation, and prometastatic signaling:

  • Immune checkpoint proteins (PD-L1, CTLA-4 pathways)

  • Tumor-promoting cytokines and chemokines (IL-6, IL-8, TNF-α)

  • Angiogenesis factors (VEGF, FGF)

  • Tumor microenvironment and prometastatic signals

  • Inflammatory and metabolic stress markers

Download a Sample Report

How It Works

Process

From registration to results, the process is simple, secure, and stress-free. One blood draw gives you answers that imaging can’t.

01

Order & Registration

Patient registers through Persona Biomed’s secure portal.

02

Sample Collection

Standard blood draw performed at an approved lab or mobile phlebotomy.

03

Laboratory Analysis

Advanced assays quantify immune and prometastatic biomarker activity.

04

Results Delivery

Detailed physician-ready report delivered via the portal with AI-powered patient summaries.

Who Should Consider This Test

who is this for

This test is intended for individuals who may be at risk, are experiencing related symptoms, or wish to take a proactive approach to their health, such as:

  • Individuals at elevated risk of breast cancer due to family history or genetic predisposition.

  • Patients with abnormal imaging or biopsy results requiring deeper molecular insight.

  • Women in remission seeking recurrence monitoring through immune-molecular tracking.

  • Individuals pursuing precision oncology treatment plans.

Register Now for
Breast Immunocarcinogenic Assay

Register now for the Breast Immunocarcinogenic Assay to uncover hidden immune signals of breast cancer and take a proactive step toward personalized cancer care

Register now